Ji Hua
Overview
Explore the profile of Ji Hua including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang X, Jiang W, Richter J, Bates J, Reznik S, Stachura S, et al.
J Med Chem
. 2024 Feb;
67(5):3571-3589.
PMID: 38385264
PAR4 is a promising antithrombotic target with potential for separation of efficacy from bleeding risk relative to current antiplatelet therapies. In an effort to discover a novel PAR4 antagonist chemotype,...
2.
Priestley E, Banville J, Deon D, Dube L, Gagnon M, Guy J, et al.
J Med Chem
. 2022 Jun;
65(13):8843-8854.
PMID: 35729784
Protease-activated receptor 4 (PAR4) is a G-protein coupled receptor that is expressed on human platelets and activated by the coagulation enzyme thrombin. PAR4 plays a key role in blood coagulation,...
3.
Li H, Zhirong Z, Shibo Z, Lichen Z, Ming S, Hua J, et al.
Dig Dis Sci
. 2022 Apr;
68(1):147-154.
PMID: 35430701
Objective: This study explored the therapeutic and protective effects of umbilical cord mesenchymal stem cells (ucMSCs) on traumatic pancreatitis (TP) to provide a theoretical basis for TP treatment with MCSs...
4.
Yang J, Mapelli C, Wang Z, Sum C, Hua J, Lawrence R, et al.
Platelets
. 2022 Mar;
33(7):979-986.
PMID: 35343875
Protease-activated receptor 4 (PAR4) is a promising drug target to improve the efficacy/safety window of antiplatelet agents. The native peptide GYPGQV, and the more-potent peptide AYPGKF, are PAR4-specific activators. However,...
5.
Wong P, Seiffert D, Bird J, Watson C, Bostwick J, Giancarli M, et al.
Sci Transl Med
. 2017 Jan;
9(371).
PMID: 28053157
Antiplatelet agents are proven efficacious treatments for cardiovascular and cerebrovascular diseases. However, the existing drugs are compromised by unwanted and sometimes life-threatening bleeding that limits drug usage or dosage. There...
6.
Xu Y, Hua J, Ni Z, Chen Q, Fan Y, Ananiadou S, et al.
PLoS One
. 2014 Oct;
9(10):e108396.
PMID: 25343498
References to anatomical entities in medical records consist not only of explicit references to anatomical locations, but also other diverse types of expressions, such as specific diseases, clinical tests, clinical...
7.
Qiao J, Wang T, Hiebert S, Hu C, Schumacher W, Spronk S, et al.
ChemMedChem
. 2014 Jul;
9(10):2327-43.
PMID: 24989964
Current antithrombotic discovery efforts target compounds that are highly efficacious in thrombus reduction with less bleeding liability than the standard of care. Preclinical data suggest that P2Y1 antagonists may have...
8.
Yang W, Wang Y, Lai A, Qiao J, Wang T, Hua J, et al.
J Med Chem
. 2014 Jun;
57(14):6150-64.
PMID: 24931384
Adenosine diphosphate (ADP)-mediated platelet aggregation is signaled through two distinct G protein-coupled receptors (GPCR) on the platelet surface: P2Y12 and P2Y1. Blocking P2Y12 receptor is a clinically well-validated strategy for...
9.
Hu C, Qiao J, Han Y, Wang T, Hua J, Price L, et al.
Bioorg Med Chem Lett
. 2014 Apr;
24(11):2481-5.
PMID: 24767843
Blockade of the P2Y1 receptor is important to the treatment of thrombosis with potentially improved safety margins compared with P2Y12 receptor antagonists. Investigation of a series of urea surrogates of...
10.
Jeon Y, Yang W, Qiao J, Li L, Ruel R, Thibeault C, et al.
Bioorg Med Chem Lett
. 2014 Feb;
24(5):1294-8.
PMID: 24513044
Spiropiperidine indoline-substituted diaryl ureas had been identified as antagonists of the P2Y1 receptor. Enhancements in potency were realized through the introduction of a 7-hydroxyl substitution on the spiropiperidinylindoline chemotype. SAR...